Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Adult
Aged
Antidepressive Agents
/ administration & dosage
Depressive Disorder, Major
/ drug therapy
Depressive Disorder, Treatment-Resistant
/ drug therapy
Female
Humans
Infusions, Intravenous
Ketamine
/ administration & dosage
Middle Aged
Outcome Assessment, Health Care
Pilot Projects
Psychiatric Status Rating Scales
Remission Induction
Severity of Illness Index
(R)-Ketamine
Arketamine
Ketamine
Major depressive disorder
Rapid-acting antidepressant
Treatment-resistant depression
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
23
12
2019
accepted:
04
02
2020
pubmed:
23
2
2020
medline:
9
11
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.
Identifiants
pubmed: 32078034
doi: 10.1007/s00406-020-01110-5
pii: 10.1007/s00406-020-01110-5
doi:
Substances chimiques
Antidepressive Agents
0
Ketamine
690G0D6V8H
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577-582Subventions
Organisme : Programa de Pesquisa para o SUS
ID : 003/2017
Références
Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. https://doi.org/10.1016/S0006-3223(99)00230-9
doi: 10.1016/S0006-3223(99)00230-9
pubmed: 10686270
Caddy C, Amit BH, McCloud TL et al (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011612.pub2
doi: 10.1002/14651858.CD011612.pub2
pubmed: 26415966
Xu Y, Hackett M, Carter G et al (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyv124
doi: 10.1093/ijnp/pyv124
pubmed: 27521242
pmcid: 5737867
Zarate CA, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856. https://doi.org/10.1001/archpsyc.63.8.856
doi: 10.1001/archpsyc.63.8.856
pubmed: 16894061
Popova V, Daly EJ, Trivedi M et al (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.2019.19020172
doi: 10.1176/appi.ajp.2019.19020172
pubmed: 31569984
Canuso CM, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620–630. https://doi.org/10.1176/appi.ajp.2018.17060720
doi: 10.1176/appi.ajp.2018.17060720
pubmed: 29656663
Correia-Melo FS, Argolo FC, Araújo-de-Freitas L et al (2017) Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat 13:1627–1632. https://doi.org/10.2147/NDT.S135623
doi: 10.2147/NDT.S135623
pubmed: 28790825
pmcid: 5488770
Correia-Melo FS, Leal GC, Vieira F et al (2019) Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. https://doi.org/10.1016/j.jad.2019.11.086
doi: 10.1016/j.jad.2019.11.086
pubmed: 31786030
Fond G, Loundou A, Rabu C et al (2014) Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology 231:3663–3676. https://doi.org/10.1007/s00213-014-3664-5
doi: 10.1007/s00213-014-3664-5
pubmed: 25038867
Lee EE, Della Selva MP, Liu A, Himelhoch S (2015) Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 37:178–184. https://doi.org/10.1016/j.genhosppsych.2015.01.003
doi: 10.1016/j.genhosppsych.2015.01.003
pubmed: 25698228
McGirr A, Berlim MT, Bond DJ et al (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:693–704. https://doi.org/10.1017/S0033291714001603
doi: 10.1017/S0033291714001603
pubmed: 25010396
Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
doi: 10.1176/appi.ajp.2013.13030392
pubmed: 23982301
pmcid: 3992936
Singh JB, Fedgchin M, Daly E et al (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80:424–431. https://doi.org/10.1016/j.biopsych.2015.10.018
doi: 10.1016/j.biopsych.2015.10.018
pubmed: 26707087
Traynor K (2019) Esketamine nasal spray approved for treatment-resistant depression. Am J Heal Pharm 76:573–573. https://doi.org/10.1093/ajhp/zxz065
doi: 10.1093/ajhp/zxz065
Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141. https://doi.org/10.1016/j.pbb.2013.11.033
doi: 10.1016/j.pbb.2013.11.033
pubmed: 24316345
Yang C, Shirayama Y, Zhang J et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632–e632. https://doi.org/10.1038/tp.2015.136
doi: 10.1038/tp.2015.136
pubmed: 26327690
pmcid: 5068814
Fukumoto K, Toki H, Iijima M et al (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361:9–16. https://doi.org/10.1124/jpet.116.239228
doi: 10.1124/jpet.116.239228
pubmed: 28115553
Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19:83–92. https://doi.org/10.1080/14737175.2019.1554434
doi: 10.1080/14737175.2019.1554434
pubmed: 30513009
Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. https://doi.org/10.1111/pcn.12902
doi: 10.1111/pcn.12902
pubmed: 31793131
pmcid: 7065166
Yang C, Han M, Zhang JC et al (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283. https://doi.org/10.1016/j.psychres.2016.03.034
doi: 10.1016/j.psychres.2016.03.034
pubmed: 27043274
Zanos P, Moaddel R, Morris PJ et al (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660. https://doi.org/10.1124/pr.117.015198
doi: 10.1124/pr.117.015198
pubmed: 29945898
pmcid: 6020109
White PF, Shafer A, Stanski DR, Horai Y (1985) Comparative pharmacology of the ketamine isomers: studies in volunteers. Br J Anaesth. https://doi.org/10.1093/bja/57.2.197
doi: 10.1093/bja/57.2.197
pubmed: 3893493
White PF, Ham J, Way WL, Trevor AJ (1980) Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52:231–239
doi: 10.1097/00000542-198003000-00008
Vollenweider FX, Leenders KL, Oye I et al (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38
doi: 10.1016/S0924-977X(96)00042-9
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389. https://doi.org/10.1192/bjp.134.4.382
doi: 10.1192/bjp.134.4.382
pubmed: 444788
Bremner JD, Krystal JH, Putnam FW et al (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11:125–136. https://doi.org/10.1023/A:1024465317902
doi: 10.1023/A:1024465317902
pubmed: 9479681
Han Y, Chen J, Zou D et al (2016) Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 12:2859–2867. https://doi.org/10.2147/NDT.S117146
doi: 10.2147/NDT.S117146
pubmed: 27843321
pmcid: 5098773
Zheng W, Cai D, Xiang Y et al (2020) Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 265:63–70. https://doi.org/10.1016/j.jad.2020.01.002
doi: 10.1016/j.jad.2020.01.002
pubmed: 31957693
Daly EJ, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry 75:139. https://doi.org/10.1001/jamapsychiatry.2017.3739
doi: 10.1001/jamapsychiatry.2017.3739
pubmed: 29282469
Fedgchin M, Trivedi M, Daly EJ et al (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22:616–630. https://doi.org/10.1093/ijnp/pyz039
doi: 10.1093/ijnp/pyz039
pubmed: 31290965
pmcid: 6822141
Hashimoto K, Kakiuchi T, Ohba H et al (2017) Reduction of dopamine D 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267:173–176. https://doi.org/10.1007/s00406-016-0692-7
doi: 10.1007/s00406-016-0692-7
pubmed: 27091456